"Triamterene"

Effects of Triamterene in Hospitalized Patients with Heart Failure and Diuretic Resistance: A Randomized Clinical Trial. Due to the potential benefits of triamterene in diuretic resistance, this study was performed to assess whether triamterene add-on to the standard treatment of heart failure (HF)-related diuretic resistance improves outcomes. A randomized clinical trial was performed on 45 hospitalized patients with HF with reduced ejection fraction who had diuretic resistance. Patients were randomized to receive either triamterene 50 mg plus hydrochlorothiazide 25 mg (n = 23) or hydrochlorothiazide 50 mg alone (n = 22) until hospital discharge. The primary outcomes were changes in weight and fluid input-to-output ratio. Secondary outcomes were respiratory rate, hospitalization duration, serum

Triamterene An official website of the United States government Here's how you know Log inAccess keysNCBI HomepageMyNCBI HomepageMain ContentMain NavigationBookshelfSearch databaseBooksAll DatabasesAssemblyBiocollectionsBioProjectBioSampleBooksClinVarConserved DomainsdbGaPdbVarGeneGenomeGEO DataSetsGEO ProfilesGTRHomoloGeneIdentical Protein GroupsMedGenMeSHNLM LactationBecause there is no published experience with triamterene during breastfeeding, other agents may be preferred, especially while nursing a newborn or preterm infant.Drug LevelsRelevant published information was not found as of the revision date.Effects in Breastfed InfantsRelevant published information was not found as of the revision date.Effects on Lactation and BreastmilkIntense diuresis can suppress

Severe Acquired Hypokalemic Paralysis in a Bodybuilder After Self-Medication With Triamterene/Hydrochlorothiazide. Severe hypokalemia with severe neurological impairment and electrocardiogram (ECG) abnormalities due to the misuse of triamterene/hydrochlorothiazide (HCTZ) in a bodybuilder has not yet been reported. A 22-year-old bodybuilder developed acute generalized muscle cramps, sensory disturbance of the distal lower and upper limbs, quadriparesis, and urinary retention. These abnormalities were attributed to severe hypokalemia of 1.8 mmol/L (normal range 3.4-4.5 mmol/L) due to misuse of triamterene/HCTZ together with fluid restriction. He was cardiologically asymptomatic, but ECG revealed a corrected QT (QTc) interval of 625 ms. On intravenous application of fluids along with intravenous

Structural studies of crystalline forms of triamterene with carboxylic acid, GRAS and API molecules Pharmaceutical salt solvates (dimethyl sulfoxide, DMSO) of the drug triamterene with the coformers acetic, succinic, adipic, pimelic, azelaic and nicotinic acid and ibuprofen are prepared by liquid-assisted grinding and solvent-evaporative crystallization. The modified Δp rule as proposed by Cruz of the crystal structures showed that all adducts existed as salt solvates and contained the amino-pyridinium-carboxyl-ate heterodimer, except for the solvate containing triamterene, ibuprofen and DMSO, as a result of the presence of a strong and stable hemitriamterenium duplex. A search of the Cambridge Structural Database (CSD 5.36, Version 1.18) to determine the frequency of occurrence of the putative

Raman Spectroscopy for the Diagnosis of Intratubular Triamterene Crystallization

Investigation of triamterene as an inhibitor of the TGR5 receptor: identification in cells and animals G-protein-coupled bile acid receptor 1 (GPBAR1, also known as TGR5) has been shown to participate in glucose homeostasis. In animal models, a TGR5 agonist increases incretin secretion to reduce hyperglycemia. Many agonists have been developed for clinical use. However, the effects of TGR5 blockade have not been studied extensively, with the exception of studies using TGR5 knockout mice. Therefore, we investigated the potential effect of triamterene on TGR5. We transfected the TGR5 gene into cultured Chinese hamster ovary cells (CHO-K1 cells) to express TGR5. Then, we applied a fluorescent indicator to examine the glucose uptake of these transfected cells. In addition, NCI-H716 cells

Modulatory effects of hydrochlorothiazide and triamterene on resistant hypertension patients The present study explored the modulatory potential of hydrochlorothiazide and triamterene on resistant hypertension patients. The mechanistic information for resistant hypertension was explored by studying the pressure-natriuresis curves between the salt sensitive population and non-salt sensitive viz. salt sensitive (SS) and non-SS (NSS) groups. These two groups were further classified into four subgroups based on the diuretic drug used. Hydrochlorothiazide-treated subgroups were named as salt sensitive hydrochlorothiazide (SSHy) and non-SSHy (NSSHy) groups. Similarly, triamterene-treated subgroups were named as salt sensitive triamterene (SSTr) and non-SSTr (NSSTr) groups. Treatment

Drug-repositioning screens identify Triamterene as a selective drug for the treatment of DNA Mismatch Repair deficient cells. The DNA mismatch repair (MMR) pathway is required for the maintenance of genome stability. Unsurprisingly, mutations in MMR genes occur in a wide range of different cancers. Studies thus far have largely focused on specific tumor types or MMR mutations; however , it is becoming increasingly clear that a therapy targeting MMR deficiency in general would be clinically very beneficial. Based on a drug-repositioning approach, we screened a large panel of cell lines with various MMR deficiencies from a range of different tumor types with a compound drug library of previously approved drugs. We have identified the potassium-sparing diuretic drug triamterene, as a novel

Triamterene Enhances the Blood Pressure Lowering Effect of Hydrochlorothiazide in Patients with Hypertension. Triamterene, because of its potassium-sparing properties, is frequently used in combination with hydrochlorothiazide (HCTZ) to treat patients with hypertension. By inhibiting the epithelial sodium channel (ENaC) in the cortical collecting duct, triamterene reduces potassium secretion , thus reducing the risk of hypokalemia. Whether triamterene has an independent effect on blood pressure (BP) has not been well studied. To determine if triamterene provides an effect to further lower BP in patients treated with HCTZ. We conducted an observational study using electronic medical record data from the Indiana Network for Patient Care. Participants were 17,291 patients with the diagnosis

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication. This is a non-randomized, non-interventional study

acetazolamide, allopurinol, aluminium magnesium hydroxide, ascorbic acid, calcium, furosemide, laxatives, vitamin D, and topiramate. * Drugs that crystallize in urine include allopurinol/oxypurinol, amoxicillin/ampicillin, ceftriaxone, quinolones, ephedrine, indinavir, magnesium trisilicate, sulphonamides, triamterene, and zonisamide. The content on the NICE Clinical Knowledge Summaries site (CKS

, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. (1)  Interfering drugs which can affect renin, aldosterone or both should be stopped for at least o 4 weeks: Spironolactone, eplerenone, amiloride, and triamterene, potassium-wasting diuretics, licorice. o 2 weeks: Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, renin inhibitors

pregnancy if they were started before pregnancy and there is no good alternative. (low GRADE)11.Only if there is a strict indication for potassium-sparing diuretics, consider prescribing amiloride during pregnancy. Avoid triamterene and aldosterone antagonists (e.g. spironolactone) during pregnancy due to the risk of severe teratogenic effects. (no GRADE)12.Choice of antihypertensives (Table 1; no GRADE

, creatinine or potassium do rise excessively consider stopping concomitant nephrotoxic drugs (for example, NSAIDs), other potassium supplements or retaining agents (triamterene, amiloride, spironolactone, eplerenone) and, if there are no signs of congestion, reducing the dose of diuretic. If greater rises in creatinine or potassium persist despite adjustment of concomitant medications, the dose of the ACE